This study suggests that derivative 13 can help to overcome acquired EGFR tyrosine kinase inhibitor resistance in EGFR mutant NSCLC by increasing the level of NO through its unique chemical structure. This evidence concerns the gene EGFR and non-small cell lung carcinoma.